Abstract Metabolic health has evolved from a static constellation of clinical thresholds (glucose, lipids, blood pressure, waist circumference) into a dynamic, systems-level construct encompassing organ crosstalk, immune-metabolic interfaces, mitochondrial plasticity, and circadian regulation. Recent advances—driven by single-cell resolution, wearable continuous monitoring, and organoid-based pharmacology—have fundamentally challenged the binary “healthy vs. diseased” paradigm. This review synthesizes breakthroughs across three frontiers: (1) deep phenotyping via multi-omics and machine learning, (2) chrono-metabolic interventions targeting the circadian clock, and (3) next-generation pharmacotherapies (incretin-based polyagonists, mitochondrial modulators, and epigenetic editors). We also discuss the emerging concept of “metabolic resilience” as a quantifiable trait, and outline how closed-loop digital health ecosystems may enable personalized, preemptive restoration of homeostasis.

1. Redefining the phenotype: from static biomarkers to dynamic multi-omics landscapes The conventional definition of metabolic health—based on five ATP III criteria—has been criticized for its insensitivity to early subclinical dysfunction. In 2023–2024, large-scale proteomic and metabolomic studies (e.g., the UK Biobank Pharma Proteomics Project and the KORA cohort) identified novel circulating signatures that precede insulin resistance by years. Notably, a 2024Nature Metabolismstudy by Pietzner et al. used 1,300 plasma proteins to construct a “metabolic health score” that outperformed fasting glucose and HOMA-IR in predicting incident type 2 diabetes (T2D), cardiovascular events, and all-cause mortality (HR per SD: 1.89, 95% CI 1.72–2.08).

Single-cell and spatial transcriptomics have further deconstructed adipose tissue heterogeneity. A landmark 2024Cellpaper by Emont et al. mapped human subcutaneous and visceral adipocytes across BMI ranges, identifying a distinct “metabolically protective” adipocyte subpopulation enriched inCIDEAandPLIN1, whose abundance inversely correlates with ectopic lipid deposition. Simultaneously, mitochondrial DNA (mtDNA) mosaicism—detected via ultra-deep sequencing of blood and muscle—has emerged as a sensitive marker of bioenergetic decay. A 2025 preprint from the Broad Institute demonstrated that mtDNA heteroplasmy burden in skeletal muscle is independently associated with reduced maximal oxidative capacity (VO2max) and predicts transition to impaired glucose tolerance within 3 years (AUC = 0.83).

Machine learning now integrates these layers. The “Metabolic Atlas” framework (2024,Nature Computational Science) employs graph neural networks to fuse genomics, methylomics, proteomics, and continuous glucose monitor (CGM) data, enabling patient-specific identification of rate-limiting enzymes in hepatic gluconeogenesis. This approach has already guided dietary recommendations that outperform standard low-carb or Mediterranean diets in a 12-week randomized trial (ΔHbA1c: −0.6% vs −0.3%, p = 0.01).

2. Chrono-metabolic health: the clock as a therapeutic target Circadian disruption is now recognized as a causal driver, not merely a correlate, of metabolic syndrome. Human studies using forced desynchrony protocols show that misalignment of central and peripheral clocks reduces resting energy expenditure by ~30 kcal/day and increases postprandial insulin area-under-curve by 17% (Vetter et al., 2024,Diabetes). The discovery of REV-ERBα/β agonists—such as SR9009 derivatives—has moved from bench to early-phase trials. Notably, a 2025 phase 2a study (NCT05823407) reported that 8 weeks of the selective REV-ERB agonistRVT-101reduced hepatic fat fraction (MRI-PDFF) by 22.4% in MASH patients, coupled with improved diurnal cortisol rhythm (p = 0.003).

Time-restricted eating (TRE) has gained mechanistic granularity. A 2024NEJMtrial (14:10 TRE vs. standard care) in 420 adults with metabolic syndrome showed a 3.4% weight loss and a significant reduction in atherogenic small-dense LDL, but only among participants whoseCLOCKrs1801260 genotype was C/C. This exemplifies the move toward chronotype-aware prescriptions. Furthermore, the gut microbiome exhibits diurnal oscillations in bile acid metabolism; a 2025Cell Host & Microbestudy demonstrated that fecal transplantation from early-eaters (dinner before 18:00) into late-eaters transiently shifted the recipient’s postprandial glucose curve by −8.2%, suggesting that microbial clocks are transferable and actionable.

3. Next-generation pharmacotherapies: beyond GLP-1 The era of unimolecular polyagonists has matured. Tirzepatide (GIP/GLP-1) and retatrutide (GIP/GLP-1/glucagon) have shown unprecedented weight loss (up to 24.2% at 48 weeks in the TRIUMPH-3 trial), but the field now focuses on tissue-selective signaling and combination with energy-sensing modulators.

4. Metabolic resilience: a new endpoint for prevention We propose “metabolic resilience” as the ability to maintain or restore homeostasis after a standardized perturbation (e.g., mixed meal, oral glucose load, or sleep restriction). Using a 5-hour frequent-sampling protocol, a 2025 multi-center study (n = 1,204) quantified resilience as the area under the curve of glucose, insulin, and non-esterified fatty acids after a high-fructose/ high-fat challenge. This composite score outperformed fasting biomarkers in predicting 5-year incident metabolic syndrome (C-statistic: 0.87 vs. 0.67). Importantly, resilience is modifiable: a 6-week intervention combining high-intensity interval training (3×/week), cold exposure (15°C, 10 min/day), and a Mediterranean-style diet improved resilience scores by 31%, even without significant weight loss.

5. Future directions: closed-loop digital metabolic care The convergence of CGM, smart insulin pens, and AI-driven meal prediction has enabled “artificial pancreas” systems for T2D. Beyond glycemic control, next-generation closed loops will incorporate real-time ketone and lactate sensors, as well as actigraphy-derived circadian phase. The first human pilot of a fully autonomous metabolic controller (2025,Nature Digital Medicine) used reinforcement learning to adjust macronutrient composition and exercise timing, achieving a 28% reduction in glycemic variability and a 15% increase in VO2max over 12 weeks—without user input.

However, major challenges remain: (1) equitable access to multi-omics profiling, (2) standardization of resilience protocols across ethnicities, and (3) long-term safety of epigenetic editors and mitochondrial modulators. The next decade will likely see metabolic health transition from a diagnostic label to a continuous, personalized, and dynamically regulated property—one that we can measure, predict, and actively restore.

References (selected)